literature

HIV mutation literature information.

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.

PMID: 35300056 2022 Pharmacogenomics and personalized medicine

Result: NGS was more sensitive in detecting low-frequency mutations and a total of 4 mutations were detected by NGS but missed by Sanger sequencing which including M184V (1.31%), K65E (3.72%), E138G (1.21%), and Y188C (1.04%).

High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.

PMID: 35215866 2022 Viruses

Result: The drug with the highest levels of resistance was Lamivudine (3TC), with 41% of the participants having the M184I and/or K65ER mutations.

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: K65R/E

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.

PMID: 33200210 2021 The Journal of antimicrobial chemotherapy

Abstract: Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively.

Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.

PMID: 33734374 2021 The Journal of antimicrobial chemotherapy

Abstract: METHODS: We included vertically HIV-infected youths/young adults aged >=10 years in the Madrid C

Result: All carried M184V mutation in their historic plasma (point 1 in Table 1), but no K65R/N/E mutations.

Discussion: Only 3/12 patients (25%) with pDNA sequence under study presented the M184V mutation in their pDNA and none presented K65R/E/N.

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.

PMID: 34064774 2021 Viruses

Method: Tenofovir-associated mutations were defined as A62V, K65R/N/E, S68G/N/D, T69 deletions, and K70E/Q/N/T/S/G.

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.

PMID: 34327247 2021 Open forum infectious diseases

Method: The role of any non-TAM was not specifically studied because of the low number of patients harboring the K65R/E/N mutation (the only other non-TAM associated with decreased susceptibility to 3TC) and its collinearity with M184V/I.

Table: K65R/E

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.

PMID: 34397746 2021 Journal of acquired immune deficiency syndromes (1999)

Method: Participants had an estimated glomerular filtration rate (eGFR) >=50 mL per minute (calculated by the Cockcroft-Gault equation) and no documented history of resistance to INSTIs or tenofovir (TFV) resistance defined as K65R/E/N mutations, >=3 thymidine analog mutations, or T69 insertions (See Appendix, Supplemental Digital Content, http://links.lww.com/QAI/B674).

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.

PMID: 34622871 2021 Medicine

Result: M184 V/I 87 (28.8%), K65R/E/N 27 (8.9%), L74 V 3 (1.0%), and Y115F 12 (4.0%) were the mutations conferring resistance to NRTIs, along with thymidine analog mutations (TAMs) M41L 14 (4.6%), D67N 17 (5.6%), K70R 20 (6.6%), L210W 10 (3.3%), T215Y/F 23 (7.6%), K219Q/E 32 (10.6%), and K65R/E/N 27 (8.9%).

Result: K65R/E/N and K70E mutations conferred resistance to TDF and M41L, D67N,

PMID: 32119691 2020 PloS one

Table: K65R/E

Browser Board

Co-occurred Entities

Filtrator